nodes	percent_of_prediction	percent_of_DWPC	metapath
Sitaxentan—CYP2C9—Tretinoin—peripheral nervous system neoplasm	0.0821	0.302	CbGbCtD
Sitaxentan—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.0513	0.189	CbGbCtD
Sitaxentan—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.0477	0.176	CbGbCtD
Sitaxentan—CYP2C9—Cisplatin—peripheral nervous system neoplasm	0.0351	0.129	CbGbCtD
Sitaxentan—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.0219	0.0806	CbGbCtD
Sitaxentan—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.0201	0.0738	CbGbCtD
Sitaxentan—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.0137	0.0504	CbGbCtD
Sitaxentan—EDNRA—GPCRs, Other—ADGRV1—peripheral nervous system neoplasm	0.009	0.114	CbGpPWpGaD
Sitaxentan—EDNRB—Endothelin Pathways—COX2—peripheral nervous system neoplasm	0.00822	0.104	CbGpPWpGaD
Sitaxentan—EDNRA—Endothelin Pathways—COX2—peripheral nervous system neoplasm	0.00588	0.0745	CbGpPWpGaD
Sitaxentan—EDNRB—Endothelin Pathways—GNAS—peripheral nervous system neoplasm	0.0035	0.0443	CbGpPWpGaD
Sitaxentan—EDNRA—Endothelin Pathways—GNAS—peripheral nervous system neoplasm	0.0025	0.0317	CbGpPWpGaD
Sitaxentan—EDNRB—G alpha (q) signalling events—NTS—peripheral nervous system neoplasm	0.00222	0.0282	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—NTS—peripheral nervous system neoplasm	0.0022	0.0278	CbGpPWpGaD
Sitaxentan—EDNRA—EGFR-dependent Endothelin signaling events—HRAS—peripheral nervous system neoplasm	0.00217	0.0274	CbGpPWpGaD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—NTS—peripheral nervous system neoplasm	0.00199	0.0252	CbGpPWpGaD
Sitaxentan—EDNRA—G alpha (q) signalling events—NTS—peripheral nervous system neoplasm	0.00159	0.0202	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—NTS—peripheral nervous system neoplasm	0.00157	0.0199	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.00147	0.0187	CbGpPWpGaD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—NTS—peripheral nervous system neoplasm	0.00142	0.018	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.00112	0.0142	CbGpPWpGaD
Sitaxentan—CYP3A4—Codeine and Morphine Metabolism—ABCB1—peripheral nervous system neoplasm	0.00108	0.0137	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.00108	0.0136	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.00105	0.0133	CbGpPWpGaD
Sitaxentan—EDNRB—G alpha (q) signalling events—KNG1—peripheral nervous system neoplasm	0.000999	0.0127	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—KNG1—peripheral nervous system neoplasm	0.000987	0.0125	CbGpPWpGaD
Sitaxentan—CYP3A4—Irinotecan Pathway—BCHE—peripheral nervous system neoplasm	0.000919	0.0116	CbGpPWpGaD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—KNG1—peripheral nervous system neoplasm	0.000894	0.0113	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.000803	0.0102	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.00077	0.00975	CbGpPWpGaD
Sitaxentan—EDNRA—G alpha (q) signalling events—KNG1—peripheral nervous system neoplasm	0.000715	0.00906	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—KNG1—peripheral nervous system neoplasm	0.000706	0.00894	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.000662	0.00838	CbGpPWpGaD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—KNG1—peripheral nervous system neoplasm	0.00064	0.0081	CbGpPWpGaD
Sitaxentan—EDNRB—Endothelins—HRAS—peripheral nervous system neoplasm	0.000638	0.00808	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.000634	0.00803	CbGpPWpGaD
Sitaxentan—CYP2C19—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	0.000594	0.00753	CbGpPWpGaD
Sitaxentan—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—peripheral nervous system neoplasm	0.000593	0.00751	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.000576	0.00729	CbGpPWpGaD
Sitaxentan—EDNRB—Endothelins—AKT1—peripheral nervous system neoplasm	0.000563	0.00713	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.000552	0.00699	CbGpPWpGaD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—PTPN11—peripheral nervous system neoplasm	0.000543	0.00688	CbGpPWpGaD
Sitaxentan—CYP2C9—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	0.000542	0.00686	CbGpPWpGaD
Sitaxentan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	0.000516	0.00654	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.000504	0.00638	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.00048	0.00608	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.000474	0.006	CbGpPWpGaD
Sitaxentan—EDNRA—Endothelins—HRAS—peripheral nervous system neoplasm	0.000456	0.00578	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.000454	0.00574	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	0.000441	0.00558	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.000436	0.00552	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.000412	0.00522	CbGpPWpGaD
Sitaxentan—EDNRA—Endothelins—AKT1—peripheral nervous system neoplasm	0.000403	0.0051	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	0.000403	0.0051	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.000395	0.005	CbGpPWpGaD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—PTPN11—peripheral nervous system neoplasm	0.000389	0.00492	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.000361	0.00457	CbGpPWpGaD
Sitaxentan—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	0.000357	0.00453	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.000344	0.00435	CbGpPWpGaD
Sitaxentan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	0.000341	0.00431	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.00034	0.00431	CbGpPWpGaD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—peripheral nervous system neoplasm	0.000327	0.00414	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.000326	0.00413	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	0.000315	0.00399	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.000312	0.00395	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	0.000288	0.00365	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	0.000285	0.00361	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	0.000259	0.00328	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.000258	0.00326	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	0.000249	0.00315	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000243	0.00308	CbGpPWpGaD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	0.000239	0.00303	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.000238	0.00301	CbGpPWpGaD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—peripheral nervous system neoplasm	0.000234	0.00296	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.000233	0.00295	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	0.000226	0.00286	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	0.000213	0.0027	CbGpPWpGaD
Sitaxentan—Anorexia—Cisplatin—peripheral nervous system neoplasm	0.000208	0.00032	CcSEcCtD
Sitaxentan—Migraine—Doxorubicin—peripheral nervous system neoplasm	0.000207	0.000319	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Etoposide—peripheral nervous system neoplasm	0.000207	0.000318	CcSEcCtD
Sitaxentan—Discomfort—Etoposide—peripheral nervous system neoplasm	0.000206	0.000317	CcSEcCtD
Sitaxentan—Breast disorder—Epirubicin—peripheral nervous system neoplasm	0.000206	0.000317	CcSEcCtD
Sitaxentan—Aspartate aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	0.000205	0.000316	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	0.000204	0.00258	CbGpPWpGaD
Sitaxentan—Hypotension—Cisplatin—peripheral nervous system neoplasm	0.000203	0.000313	CcSEcCtD
Sitaxentan—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	0.000203	0.000313	CcSEcCtD
Sitaxentan—Urticaria—Alitretinoin—peripheral nervous system neoplasm	0.000203	0.000313	CcSEcCtD
Sitaxentan—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	0.000202	0.000311	CcSEcCtD
Sitaxentan—Nausea—Topotecan—peripheral nervous system neoplasm	0.000202	0.000311	CcSEcCtD
Sitaxentan—Confusional state—Etoposide—peripheral nervous system neoplasm	0.000201	0.00031	CcSEcCtD
Sitaxentan—Alanine aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	0.000201	0.000309	CcSEcCtD
Sitaxentan—Muscular weakness—Epirubicin—peripheral nervous system neoplasm	0.000201	0.000309	CcSEcCtD
Sitaxentan—Nausea—Tretinoin—peripheral nervous system neoplasm	0.0002	0.000309	CcSEcCtD
Sitaxentan—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.0002	0.000309	CcSEcCtD
Sitaxentan—Infection—Etoposide—peripheral nervous system neoplasm	0.000198	0.000305	CcSEcCtD
Sitaxentan—Ataxia—Doxorubicin—peripheral nervous system neoplasm	0.000198	0.000305	CcSEcCtD
Sitaxentan—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.000198	0.000305	CcSEcCtD
Sitaxentan—Nausea—Melphalan—peripheral nervous system neoplasm	0.000198	0.000305	CcSEcCtD
Sitaxentan—Blood creatinine increased—Doxorubicin—peripheral nervous system neoplasm	0.000197	0.000304	CcSEcCtD
Sitaxentan—Asthma—Epirubicin—peripheral nervous system neoplasm	0.000197	0.000303	CcSEcCtD
Sitaxentan—Dehydration—Doxorubicin—peripheral nervous system neoplasm	0.000196	0.000302	CcSEcCtD
Sitaxentan—Thrombocytopenia—Etoposide—peripheral nervous system neoplasm	0.000195	0.000301	CcSEcCtD
Sitaxentan—Tachycardia—Etoposide—peripheral nervous system neoplasm	0.000195	0.0003	CcSEcCtD
Sitaxentan—Eosinophilia—Epirubicin—peripheral nervous system neoplasm	0.000195	0.0003	CcSEcCtD
Sitaxentan—Body temperature increased—Vincristine—peripheral nervous system neoplasm	0.000195	0.0003	CcSEcCtD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	0.000194	0.00246	CbGpPWpGaD
Sitaxentan—Liver function test abnormal—Doxorubicin—peripheral nervous system neoplasm	0.000194	0.000299	CcSEcCtD
Sitaxentan—Skin disorder—Etoposide—peripheral nervous system neoplasm	0.000194	0.000298	CcSEcCtD
Sitaxentan—Dry skin—Doxorubicin—peripheral nervous system neoplasm	0.000193	0.000297	CcSEcCtD
Sitaxentan—Abdominal pain upper—Doxorubicin—peripheral nervous system neoplasm	0.000192	0.000296	CcSEcCtD
Sitaxentan—Orthostatic hypotension—Doxorubicin—peripheral nervous system neoplasm	0.000192	0.000296	CcSEcCtD
Sitaxentan—Angina pectoris—Epirubicin—peripheral nervous system neoplasm	0.000192	0.000295	CcSEcCtD
Sitaxentan—Breast disorder—Doxorubicin—peripheral nervous system neoplasm	0.00019	0.000293	CcSEcCtD
Sitaxentan—Anorexia—Etoposide—peripheral nervous system neoplasm	0.00019	0.000293	CcSEcCtD
Sitaxentan—Aspartate aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	0.00019	0.000292	CcSEcCtD
Sitaxentan—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	0.000189	0.000292	CcSEcCtD
Sitaxentan—Bronchitis—Epirubicin—peripheral nervous system neoplasm	0.000189	0.000291	CcSEcCtD
Sitaxentan—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000189	0.000291	CcSEcCtD
Sitaxentan—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.000188	0.00029	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000188	0.00029	CcSEcCtD
Sitaxentan—Pancytopenia—Epirubicin—peripheral nervous system neoplasm	0.000187	0.000288	CcSEcCtD
Sitaxentan—Hypotension—Etoposide—peripheral nervous system neoplasm	0.000186	0.000287	CcSEcCtD
Sitaxentan—Pain—Cisplatin—peripheral nervous system neoplasm	0.000186	0.000287	CcSEcCtD
Sitaxentan—Muscular weakness—Doxorubicin—peripheral nervous system neoplasm	0.000186	0.000286	CcSEcCtD
Sitaxentan—Alanine aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	0.000186	0.000286	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	0.000185	0.00234	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.000184	0.00234	CbGpPWpGaD
Sitaxentan—Dysuria—Epirubicin—peripheral nervous system neoplasm	0.000184	0.000283	CcSEcCtD
Sitaxentan—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000183	0.000282	CcSEcCtD
Sitaxentan—Asthma—Doxorubicin—peripheral nervous system neoplasm	0.000182	0.00028	CcSEcCtD
Sitaxentan—Pollakiuria—Epirubicin—peripheral nervous system neoplasm	0.000182	0.00028	CcSEcCtD
Sitaxentan—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.000181	0.000279	CcSEcCtD
Sitaxentan—Eosinophilia—Doxorubicin—peripheral nervous system neoplasm	0.00018	0.000278	CcSEcCtD
Sitaxentan—Photosensitivity reaction—Epirubicin—peripheral nervous system neoplasm	0.000179	0.000277	CcSEcCtD
Sitaxentan—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	0.000179	0.000276	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	0.000179	0.00226	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	0.000178	0.00226	CbGpPWpGaD
Sitaxentan—Weight decreased—Epirubicin—peripheral nervous system neoplasm	0.000178	0.000274	CcSEcCtD
Sitaxentan—Hyperglycaemia—Epirubicin—peripheral nervous system neoplasm	0.000177	0.000273	CcSEcCtD
Sitaxentan—Somnolence—Etoposide—peripheral nervous system neoplasm	0.000177	0.000273	CcSEcCtD
Sitaxentan—Angina pectoris—Doxorubicin—peripheral nervous system neoplasm	0.000177	0.000273	CcSEcCtD
Sitaxentan—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000177	0.000272	CcSEcCtD
Sitaxentan—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	0.000175	0.00027	CcSEcCtD
Sitaxentan—Infestation—Epirubicin—peripheral nervous system neoplasm	0.000175	0.00027	CcSEcCtD
Sitaxentan—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000175	0.00027	CcSEcCtD
Sitaxentan—Bronchitis—Doxorubicin—peripheral nervous system neoplasm	0.000175	0.00027	CcSEcCtD
Sitaxentan—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000175	0.000269	CcSEcCtD
Sitaxentan—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000174	0.000268	CcSEcCtD
Sitaxentan—Decreased appetite—Etoposide—peripheral nervous system neoplasm	0.000173	0.000267	CcSEcCtD
Sitaxentan—Pancytopenia—Doxorubicin—peripheral nervous system neoplasm	0.000173	0.000266	CcSEcCtD
Sitaxentan—Renal failure—Epirubicin—peripheral nervous system neoplasm	0.000172	0.000266	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.000172	0.000265	CcSEcCtD
Sitaxentan—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.000172	0.000265	CcSEcCtD
Sitaxentan—Fatigue—Etoposide—peripheral nervous system neoplasm	0.000172	0.000265	CcSEcCtD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	0.000171	0.00217	CbGpPWpGaD
Sitaxentan—Stomatitis—Epirubicin—peripheral nervous system neoplasm	0.000171	0.000263	CcSEcCtD
Sitaxentan—Jaundice—Epirubicin—peripheral nervous system neoplasm	0.000171	0.000263	CcSEcCtD
Sitaxentan—Constipation—Etoposide—peripheral nervous system neoplasm	0.000171	0.000263	CcSEcCtD
Sitaxentan—Pain—Etoposide—peripheral nervous system neoplasm	0.000171	0.000263	CcSEcCtD
Sitaxentan—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	0.00017	0.000263	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.00017	0.00216	CbGpPWpGaD
Sitaxentan—Dysuria—Doxorubicin—peripheral nervous system neoplasm	0.00017	0.000262	CcSEcCtD
Sitaxentan—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000169	0.00026	CcSEcCtD
Sitaxentan—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000168	0.00026	CcSEcCtD
Sitaxentan—Pollakiuria—Doxorubicin—peripheral nervous system neoplasm	0.000168	0.000259	CcSEcCtD
Sitaxentan—Haematuria—Epirubicin—peripheral nervous system neoplasm	0.000167	0.000258	CcSEcCtD
Sitaxentan—Photosensitivity reaction—Doxorubicin—peripheral nervous system neoplasm	0.000166	0.000256	CcSEcCtD
Sitaxentan—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	0.000166	0.000255	CcSEcCtD
Sitaxentan—Epistaxis—Epirubicin—peripheral nervous system neoplasm	0.000165	0.000255	CcSEcCtD
Sitaxentan—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	0.000165	0.000254	CcSEcCtD
Sitaxentan—Sinusitis—Epirubicin—peripheral nervous system neoplasm	0.000164	0.000253	CcSEcCtD
Sitaxentan—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	0.000164	0.000253	CcSEcCtD
Sitaxentan—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	0.000164	0.000253	CcSEcCtD
Sitaxentan—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000164	0.000252	CcSEcCtD
Sitaxentan—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000163	0.000251	CcSEcCtD
Sitaxentan—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.000162	0.00025	CcSEcCtD
Sitaxentan—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	0.000162	0.00025	CcSEcCtD
Sitaxentan—Infestation—Doxorubicin—peripheral nervous system neoplasm	0.000162	0.00025	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	0.000162	0.00205	CbGpPWpGaD
Sitaxentan—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000161	0.000248	CcSEcCtD
Sitaxentan—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000161	0.000248	CcSEcCtD
Sitaxentan—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.00016	0.000247	CcSEcCtD
Sitaxentan—Bradycardia—Epirubicin—peripheral nervous system neoplasm	0.00016	0.000247	CcSEcCtD
Sitaxentan—Headache—Alitretinoin—peripheral nervous system neoplasm	0.00016	0.000247	CcSEcCtD
Sitaxentan—Renal failure—Doxorubicin—peripheral nervous system neoplasm	0.000159	0.000246	CcSEcCtD
Sitaxentan—Urticaria—Etoposide—peripheral nervous system neoplasm	0.000158	0.000244	CcSEcCtD
Sitaxentan—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	0.000158	0.000244	CcSEcCtD
Sitaxentan—Jaundice—Doxorubicin—peripheral nervous system neoplasm	0.000158	0.000244	CcSEcCtD
Sitaxentan—Stomatitis—Doxorubicin—peripheral nervous system neoplasm	0.000158	0.000244	CcSEcCtD
Sitaxentan—Rhinitis—Epirubicin—peripheral nervous system neoplasm	0.000158	0.000243	CcSEcCtD
Sitaxentan—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.000158	0.000243	CcSEcCtD
Sitaxentan—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	0.000158	0.000243	CcSEcCtD
Sitaxentan—Hepatitis—Epirubicin—peripheral nervous system neoplasm	0.000157	0.000242	CcSEcCtD
Sitaxentan—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	0.000157	0.000242	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	0.000157	0.00199	CbGpPWpGaD
Sitaxentan—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000157	0.000241	CcSEcCtD
Sitaxentan—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000156	0.000241	CcSEcCtD
Sitaxentan—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	0.000155	0.000239	CcSEcCtD
Sitaxentan—Rash—Vincristine—peripheral nervous system neoplasm	0.000155	0.000239	CcSEcCtD
Sitaxentan—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000155	0.000239	CcSEcCtD
Sitaxentan—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	0.000155	0.000239	CcSEcCtD
Sitaxentan—Haematuria—Doxorubicin—peripheral nervous system neoplasm	0.000155	0.000238	CcSEcCtD
Sitaxentan—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	0.000154	0.000238	CcSEcCtD
Sitaxentan—Headache—Vincristine—peripheral nervous system neoplasm	0.000154	0.000238	CcSEcCtD
Sitaxentan—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	0.000153	0.000236	CcSEcCtD
Sitaxentan—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	0.000153	0.000236	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—KNG1—peripheral nervous system neoplasm	0.000153	0.00193	CbGpPWpGaD
Sitaxentan—Sinusitis—Doxorubicin—peripheral nervous system neoplasm	0.000152	0.000234	CcSEcCtD
Sitaxentan—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000152	0.000234	CcSEcCtD
Sitaxentan—Visual impairment—Epirubicin—peripheral nervous system neoplasm	0.000152	0.000234	CcSEcCtD
Sitaxentan—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.000149	0.00023	CcSEcCtD
Sitaxentan—Bradycardia—Doxorubicin—peripheral nervous system neoplasm	0.000148	0.000228	CcSEcCtD
Sitaxentan—Eye disorder—Epirubicin—peripheral nervous system neoplasm	0.000147	0.000227	CcSEcCtD
Sitaxentan—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.000147	0.000226	CcSEcCtD
Sitaxentan—Tinnitus—Epirubicin—peripheral nervous system neoplasm	0.000147	0.000226	CcSEcCtD
Sitaxentan—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	0.000146	0.000225	CcSEcCtD
Sitaxentan—Nausea—Vincristine—peripheral nervous system neoplasm	0.000146	0.000225	CcSEcCtD
Sitaxentan—Flushing—Epirubicin—peripheral nervous system neoplasm	0.000146	0.000225	CcSEcCtD
Sitaxentan—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	0.000146	0.000225	CcSEcCtD
Sitaxentan—Rhinitis—Doxorubicin—peripheral nervous system neoplasm	0.000146	0.000225	CcSEcCtD
Sitaxentan—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	0.000146	0.000224	CcSEcCtD
Sitaxentan—Hepatitis—Doxorubicin—peripheral nervous system neoplasm	0.000146	0.000224	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	0.000146	0.00184	CbGpPWpGaD
Sitaxentan—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	0.000144	0.000222	CcSEcCtD
Sitaxentan—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	0.000143	0.000221	CcSEcCtD
Sitaxentan—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000143	0.00022	CcSEcCtD
Sitaxentan—Angiopathy—Epirubicin—peripheral nervous system neoplasm	0.000143	0.00022	CcSEcCtD
Sitaxentan—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	0.000143	0.00022	CcSEcCtD
Sitaxentan—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	0.000142	0.000219	CcSEcCtD
Sitaxentan—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000142	0.000219	CcSEcCtD
Sitaxentan—CYP2C19—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000141	0.00178	CbGpPWpGaD
Sitaxentan—Visual impairment—Doxorubicin—peripheral nervous system neoplasm	0.00014	0.000216	CcSEcCtD
Sitaxentan—Alopecia—Epirubicin—peripheral nervous system neoplasm	0.000139	0.000214	CcSEcCtD
Sitaxentan—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.000138	0.000213	CcSEcCtD
Sitaxentan—Mental disorder—Epirubicin—peripheral nervous system neoplasm	0.000138	0.000212	CcSEcCtD
Sitaxentan—Rash—Cisplatin—peripheral nervous system neoplasm	0.000137	0.000212	CcSEcCtD
Sitaxentan—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.000137	0.000211	CcSEcCtD
Sitaxentan—Malnutrition—Epirubicin—peripheral nervous system neoplasm	0.000137	0.000211	CcSEcCtD
Sitaxentan—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.000136	0.00021	CcSEcCtD
Sitaxentan—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	0.000136	0.00021	CcSEcCtD
Sitaxentan—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	0.000136	0.000209	CcSEcCtD
Sitaxentan—Flushing—Doxorubicin—peripheral nervous system neoplasm	0.000135	0.000208	CcSEcCtD
Sitaxentan—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	0.000135	0.000208	CcSEcCtD
Sitaxentan—Tension—Epirubicin—peripheral nervous system neoplasm	0.000134	0.000207	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—GNAS—peripheral nervous system neoplasm	0.000134	0.00169	CbGpPWpGaD
Sitaxentan—Nervousness—Epirubicin—peripheral nervous system neoplasm	0.000133	0.000205	CcSEcCtD
Sitaxentan—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	0.000132	0.000204	CcSEcCtD
Sitaxentan—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000132	0.000203	CcSEcCtD
Sitaxentan—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	0.000132	0.000203	CcSEcCtD
Sitaxentan—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000132	0.000203	CcSEcCtD
Sitaxentan—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000131	0.000202	CcSEcCtD
Sitaxentan—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000129	0.000199	CcSEcCtD
Sitaxentan—Alopecia—Doxorubicin—peripheral nervous system neoplasm	0.000129	0.000198	CcSEcCtD
Sitaxentan—CYP2C9—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000128	0.00162	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	0.000128	0.00162	CbGpPWpGaD
Sitaxentan—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	0.000128	0.000197	CcSEcCtD
Sitaxentan—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	0.000127	0.000196	CcSEcCtD
Sitaxentan—Vomiting—Etoposide—peripheral nervous system neoplasm	0.000127	0.000195	CcSEcCtD
Sitaxentan—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	0.000127	0.000195	CcSEcCtD
Sitaxentan—Anaemia—Epirubicin—peripheral nervous system neoplasm	0.000127	0.000195	CcSEcCtD
Sitaxentan—Agitation—Epirubicin—peripheral nervous system neoplasm	0.000126	0.000194	CcSEcCtD
Sitaxentan—Rash—Etoposide—peripheral nervous system neoplasm	0.000126	0.000194	CcSEcCtD
Sitaxentan—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.000126	0.000194	CcSEcCtD
Sitaxentan—Headache—Etoposide—peripheral nervous system neoplasm	0.000125	0.000193	CcSEcCtD
Sitaxentan—Tension—Doxorubicin—peripheral nervous system neoplasm	0.000124	0.000192	CcSEcCtD
Sitaxentan—Malaise—Epirubicin—peripheral nervous system neoplasm	0.000124	0.00019	CcSEcCtD
Sitaxentan—Nervousness—Doxorubicin—peripheral nervous system neoplasm	0.000123	0.00019	CcSEcCtD
Sitaxentan—Vertigo—Epirubicin—peripheral nervous system neoplasm	0.000123	0.00019	CcSEcCtD
Sitaxentan—Leukopenia—Epirubicin—peripheral nervous system neoplasm	0.000123	0.000189	CcSEcCtD
Sitaxentan—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	0.000122	0.000188	CcSEcCtD
Sitaxentan—Nausea—Etoposide—peripheral nervous system neoplasm	0.000118	0.000183	CcSEcCtD
Sitaxentan—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	0.000118	0.000181	CcSEcCtD
Sitaxentan—Anaemia—Doxorubicin—peripheral nervous system neoplasm	0.000117	0.000181	CcSEcCtD
Sitaxentan—Chest pain—Epirubicin—peripheral nervous system neoplasm	0.000117	0.00018	CcSEcCtD
Sitaxentan—Agitation—Doxorubicin—peripheral nervous system neoplasm	0.000117	0.000179	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	0.000116	0.000178	CcSEcCtD
Sitaxentan—Discomfort—Epirubicin—peripheral nervous system neoplasm	0.000115	0.000178	CcSEcCtD
Sitaxentan—Malaise—Doxorubicin—peripheral nervous system neoplasm	0.000114	0.000176	CcSEcCtD
Sitaxentan—Dry mouth—Epirubicin—peripheral nervous system neoplasm	0.000114	0.000176	CcSEcCtD
Sitaxentan—Vertigo—Doxorubicin—peripheral nervous system neoplasm	0.000114	0.000175	CcSEcCtD
Sitaxentan—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	0.000113	0.000175	CcSEcCtD
Sitaxentan—Confusional state—Epirubicin—peripheral nervous system neoplasm	0.000113	0.000174	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	0.000112	0.00142	CbGpPWpGaD
Sitaxentan—Oedema—Epirubicin—peripheral nervous system neoplasm	0.000112	0.000172	CcSEcCtD
Sitaxentan—Infection—Epirubicin—peripheral nervous system neoplasm	0.000111	0.000171	CcSEcCtD
Sitaxentan—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	0.00011	0.000169	CcSEcCtD
Sitaxentan—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	0.000109	0.000169	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—KNG1—peripheral nervous system neoplasm	0.000109	0.00138	CbGpPWpGaD
Sitaxentan—Tachycardia—Epirubicin—peripheral nervous system neoplasm	0.000109	0.000168	CcSEcCtD
Sitaxentan—Skin disorder—Epirubicin—peripheral nervous system neoplasm	0.000109	0.000167	CcSEcCtD
Sitaxentan—Chest pain—Doxorubicin—peripheral nervous system neoplasm	0.000108	0.000166	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	0.000107	0.000165	CcSEcCtD
Sitaxentan—Discomfort—Doxorubicin—peripheral nervous system neoplasm	0.000107	0.000164	CcSEcCtD
Sitaxentan—Anorexia—Epirubicin—peripheral nervous system neoplasm	0.000107	0.000164	CcSEcCtD
Sitaxentan—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	0.000106	0.000163	CcSEcCtD
Sitaxentan—Hypotension—Epirubicin—peripheral nervous system neoplasm	0.000104	0.000161	CcSEcCtD
Sitaxentan—Confusional state—Doxorubicin—peripheral nervous system neoplasm	0.000104	0.000161	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	0.000104	0.00132	CbGpPWpGaD
Sitaxentan—Oedema—Doxorubicin—peripheral nervous system neoplasm	0.000103	0.000159	CcSEcCtD
Sitaxentan—Infection—Doxorubicin—peripheral nervous system neoplasm	0.000103	0.000158	CcSEcCtD
Sitaxentan—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000101	0.000156	CcSEcCtD
Sitaxentan—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	0.000101	0.000156	CcSEcCtD
Sitaxentan—Insomnia—Epirubicin—peripheral nervous system neoplasm	0.000101	0.000156	CcSEcCtD
Sitaxentan—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	0.000101	0.000156	CcSEcCtD
Sitaxentan—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	0.0001	0.000155	CcSEcCtD
Sitaxentan—Somnolence—Epirubicin—peripheral nervous system neoplasm	9.94e-05	0.000153	CcSEcCtD
Sitaxentan—Anorexia—Doxorubicin—peripheral nervous system neoplasm	9.86e-05	0.000152	CcSEcCtD
Sitaxentan—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	9.84e-05	0.000152	CcSEcCtD
Sitaxentan—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	9.72e-05	0.00015	CcSEcCtD
Sitaxentan—Hypotension—Doxorubicin—peripheral nervous system neoplasm	9.67e-05	0.000149	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	9.65e-05	0.000149	CcSEcCtD
Sitaxentan—Fatigue—Epirubicin—peripheral nervous system neoplasm	9.64e-05	0.000149	CcSEcCtD
Sitaxentan—Constipation—Epirubicin—peripheral nervous system neoplasm	9.56e-05	0.000147	CcSEcCtD
Sitaxentan—Pain—Epirubicin—peripheral nervous system neoplasm	9.56e-05	0.000147	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—GNAS—peripheral nervous system neoplasm	9.56e-05	0.00121	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—HSD17B12—peripheral nervous system neoplasm	9.5e-05	0.0012	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	9.45e-05	0.0012	CbGpPWpGaD
Sitaxentan—Insomnia—Doxorubicin—peripheral nervous system neoplasm	9.36e-05	0.000144	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	9.28e-05	0.00118	CbGpPWpGaD
Sitaxentan—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	9.21e-05	0.000142	CcSEcCtD
Sitaxentan—Somnolence—Doxorubicin—peripheral nervous system neoplasm	9.2e-05	0.000142	CcSEcCtD
Sitaxentan—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	9.11e-05	0.00014	CcSEcCtD
Sitaxentan—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	8.99e-05	0.000139	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	8.93e-05	0.000138	CcSEcCtD
Sitaxentan—Fatigue—Doxorubicin—peripheral nervous system neoplasm	8.92e-05	0.000137	CcSEcCtD
Sitaxentan—Urticaria—Epirubicin—peripheral nervous system neoplasm	8.88e-05	0.000137	CcSEcCtD
Sitaxentan—Constipation—Doxorubicin—peripheral nervous system neoplasm	8.85e-05	0.000136	CcSEcCtD
Sitaxentan—Pain—Doxorubicin—peripheral nervous system neoplasm	8.85e-05	0.000136	CcSEcCtD
Sitaxentan—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	8.84e-05	0.000136	CcSEcCtD
Sitaxentan—CYP2C9—Metabolism—HSD17B12—peripheral nervous system neoplasm	8.66e-05	0.0011	CbGpPWpGaD
Sitaxentan—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	8.53e-05	0.000131	CcSEcCtD
Sitaxentan—CYP3A4—Metabolism—PPIP5K2—peripheral nervous system neoplasm	8.45e-05	0.00107	CbGpPWpGaD
Sitaxentan—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	8.24e-05	0.000127	CcSEcCtD
Sitaxentan—Urticaria—Doxorubicin—peripheral nervous system neoplasm	8.22e-05	0.000127	CcSEcCtD
Sitaxentan—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	8.18e-05	0.000126	CcSEcCtD
Sitaxentan—Asthenia—Epirubicin—peripheral nervous system neoplasm	8.02e-05	0.000124	CcSEcCtD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	7.89e-05	0.001	CbGpPWpGaD
Sitaxentan—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	7.65e-05	0.000118	CcSEcCtD
Sitaxentan—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	7.62e-05	0.000117	CcSEcCtD
Sitaxentan—Asthenia—Doxorubicin—peripheral nervous system neoplasm	7.42e-05	0.000114	CcSEcCtD
Sitaxentan—Dizziness—Epirubicin—peripheral nervous system neoplasm	7.39e-05	0.000114	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	7.34e-05	0.000929	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	7.2e-05	0.000911	CbGpPWpGaD
Sitaxentan—Vomiting—Epirubicin—peripheral nervous system neoplasm	7.11e-05	0.00011	CcSEcCtD
Sitaxentan—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	7.08e-05	0.000109	CcSEcCtD
Sitaxentan—Rash—Epirubicin—peripheral nervous system neoplasm	7.05e-05	0.000109	CcSEcCtD
Sitaxentan—Dermatitis—Epirubicin—peripheral nervous system neoplasm	7.04e-05	0.000109	CcSEcCtD
Sitaxentan—Headache—Epirubicin—peripheral nervous system neoplasm	7.01e-05	0.000108	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	6.91e-05	0.000875	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GNS—peripheral nervous system neoplasm	6.87e-05	0.00087	CbGpPWpGaD
Sitaxentan—Dizziness—Doxorubicin—peripheral nervous system neoplasm	6.84e-05	0.000105	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	6.76e-05	0.000856	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	6.72e-05	0.000851	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CASP3—peripheral nervous system neoplasm	6.66e-05	0.000843	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	6.64e-05	0.000841	CbGpPWpGaD
Sitaxentan—Nausea—Epirubicin—peripheral nervous system neoplasm	6.64e-05	0.000102	CcSEcCtD
Sitaxentan—CYP2C19—Metabolism—NME1—peripheral nervous system neoplasm	6.58e-05	0.000834	CbGpPWpGaD
Sitaxentan—Vomiting—Doxorubicin—peripheral nervous system neoplasm	6.58e-05	0.000101	CcSEcCtD
Sitaxentan—Rash—Doxorubicin—peripheral nervous system neoplasm	6.52e-05	0.0001	CcSEcCtD
Sitaxentan—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	6.52e-05	0.0001	CcSEcCtD
Sitaxentan—Headache—Doxorubicin—peripheral nervous system neoplasm	6.48e-05	9.99e-05	CcSEcCtD
Sitaxentan—CYP2C19—Metabolism—COX2—peripheral nervous system neoplasm	6.34e-05	0.000803	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GNS—peripheral nervous system neoplasm	6.26e-05	0.000793	CbGpPWpGaD
Sitaxentan—Nausea—Doxorubicin—peripheral nervous system neoplasm	6.15e-05	9.47e-05	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	6.1e-05	0.000773	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—NME1—peripheral nervous system neoplasm	6e-05	0.00076	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—COX2—peripheral nervous system neoplasm	5.78e-05	0.000732	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—HSD17B12—peripheral nervous system neoplasm	5.71e-05	0.000723	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—NRAS—peripheral nervous system neoplasm	5.58e-05	0.000707	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5.25e-05	0.000665	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—MYC—peripheral nervous system neoplasm	5.2e-05	0.000658	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	4.95e-05	0.000627	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	4.81e-05	0.000609	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.77e-05	0.000604	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	4.37e-05	0.000553	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TP53—peripheral nervous system neoplasm	4.27e-05	0.000541	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ENO2—peripheral nervous system neoplasm	4.16e-05	0.000527	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GNS—peripheral nervous system neoplasm	4.13e-05	0.000523	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—HRAS—peripheral nervous system neoplasm	4.08e-05	0.000517	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.99e-05	0.000506	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	3.96e-05	0.000501	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	3.81e-05	0.000483	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ENO2—peripheral nervous system neoplasm	3.79e-05	0.00048	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.72e-05	0.000471	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.61e-05	0.000457	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—BCHE—peripheral nervous system neoplasm	3.51e-05	0.000445	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—SLC2A1—peripheral nervous system neoplasm	3.35e-05	0.000425	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—TH—peripheral nervous system neoplasm	3.3e-05	0.000419	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—BCHE—peripheral nervous system neoplasm	3.2e-05	0.000406	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—SLC2A1—peripheral nervous system neoplasm	3.06e-05	0.000387	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.06e-05	0.000387	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—TH—peripheral nervous system neoplasm	3.01e-05	0.000382	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.92e-05	0.00037	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GNAS—peripheral nervous system neoplasm	2.7e-05	0.000342	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ABCB1—peripheral nervous system neoplasm	2.65e-05	0.000335	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.58e-05	0.000327	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	2.5e-05	0.000317	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GNAS—peripheral nervous system neoplasm	2.46e-05	0.000312	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ABCB1—peripheral nervous system neoplasm	2.41e-05	0.000306	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	2.11e-05	0.000268	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.02e-05	0.000255	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	1.99e-05	0.000252	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	1.62e-05	0.000205	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	1.59e-05	0.000202	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—AKT1—peripheral nervous system neoplasm	7.28e-06	9.22e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—AKT1—peripheral nervous system neoplasm	6.64e-06	8.41e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	4.38e-06	5.55e-05	CbGpPWpGaD
